trending Market Intelligence /marketintelligence/en/news-insights/trending/HzOfMG8QdDWnXGPJFEDlwQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Trillium closes $15M offering of units to fund cancer program

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Trillium closes $15M offering of units to fund cancer program

Trillium Therapeutics Inc. closed its offering of common shares, common share purchase warrants and preferred shares for gross proceeds of $15 million.

The Mississauga, Canada-based biotechnology company sold 6,550,000 common share units and 12.2 million series 2 nonvoting convertible first preferred share units in the offering.

The common share units were priced at 80 cents apiece and consist of a common share and a five-year common share purchase warrant, which is exercisable for a common share at 96 cents apiece. The preferred share units were also priced at 80 cents each and consist of a preferred share and a five-year series 2 preferred share purchase warrant, which is exercisable for a preferred share for 96 cents each.

The company plans to use the proceeds to fund the development of its SIRPαFc program to develop treatments for cancer and to fund working capital and general corporate purposes.

Cowen and Co. LLC was the sole book-running manager for the offering.